Bacterial Precipitins 1n Serum of Patients With Cystic Fibrosis

Letter to the Editor: Bacterial Flora and Ion Content of Cystic Fibrosis Sputum

“…The changes were from S. aureus only or S. aureus and P. aeruginosa to S. aureus and Hemophilus influenzae, S. aureus, and P. aeruginosa or P. aeruginosa only. These changes in bacterial flora are the ones predicted by the hypothesis of Bums and May (2).…”

“…Fourteen of sixteen patients with cystic fibrosis were selected for this study because: (I) they were able to cough up at least 0.2 ml of purulent sputum without postural drainage or after only brief physical therapy; (2) they were in a relatively stable clinical condition and did not require hospitalization, but no effort was made to group them as to their chemotherapy; (3) their sputum bacterial flora could be placed in one of the bacterial sputum groups suggested by Burns and May (2). Patients with cystic fibrosis who did not have one of the bacterial sputum groups suggested by Bums and May were not included in this study.…”

Mucoid Strains of Pseudomonas Aeruginosa: The Influence of Culture Medium on the Stability of Mucus Production

“…Dipalmitoyl lecithin is the major surfactant found in the human lung (Brown, 1964) and although the concentration at which maximum stabilisation occurred appears low it is approximately the same concentration as that found in normal lungs and shown in vitro to produce surfactant activity similar to that of extracts of normal lungs (Thannhauser, Bennotti and Boncoddo, 1946;Kuenzig, Hamilton and Peltier, 1965). It is perhaps significant that after pulmonary infections in CF patients the next highest incidence of mucoid P. aeruginosa also occurs in the lung in cases of chronic bronchitis (Burns and May, 1968).…”

Preimmunization Anti-Pneumococcal Antibody Levels Are Protective in a Majority of Patients With Cystic Fibrosis

“…As stated previously, a blunted antibody response to pneumococcal colonization also may be attributed to chronic antibiotic and, in particular, anti-staphylococcal therapy. 11,12 During the period of data collection, approx- imately 90% of our CF patients were receiving such therapy (A. Colin, personal communication). For these reasons, we anticipated a blunted response to pneumococcus in our CF population.…”